Published in Hepatitis Weekly, September 24th, 2007
The poster by Simmen et al. entitled "Preclinical Characterization of TMC435350, a novel macrocyclic inhibitor of the HCV NS3/4A serine protease" demonstrates the ability of the compound to reduce the amount of Hepatitis C virus (HCV) replication in laboratory replicon experiments via protease inhibition. Combination of TMC435350 with interferon is also reported to enhance RNA reduction (>4 logs reduction in the replicon model), and to suppress the appearance of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly